News
PTGX
40.28
-3.10%
-1.29
Protagonist Therapeutics Price Target Raised to $48.00/Share From $39.00 by JP Morgan
Dow Jones · 1d ago
Protagonist Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $48
Benzinga · 1d ago
PROTAGONIST THERAPEUTICS INC <PTGX.O>: JP MORGAN RAISES TARGET PRICE TO $48 FROM $39
Reuters · 1d ago
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
Shares of AT&T Inc. Rose 3.1% to $18.78 on Wednesday. The company reported second-quarter earnings in line with the analyst consensus estimate. The Dow Jones index fell around 350 points in Wednesday's session. U.S. Stocks were lower on the day.
Benzinga · 2d ago
Protagonist Therapeutics Price Target Raised to $51.00/Share From $41.00 by BTIG
Dow Jones · 2d ago
Protagonist Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 2d ago
BTIG Maintains Buy on Protagonist Therapeutics, Raises Price Target to $51
Benzinga · 2d ago
Buy Rating for Protagonist Therapeutics: Expanding Pipeline and Strong Partnership Prospects
TipRanks · 2d ago
PROTAGONIST THERAPEUTICS INC <PTGX.O>: BTIG RAISES TARGET PRICE TO $51 FROM $41
Reuters · 2d ago
Weekly Report: what happened at PTGX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at PTGX last week (0708-0712)?
Weekly Report · 07/15 11:10
Weekly Report: what happened at PTGX last week (0701-0705)?
Weekly Report · 07/08 11:11
After Hours Most Active for Jul 2, 2024 : WRK, FUN, PCG, QQQ, NVDA, PTGX, BAC, IP, VZ, MDLZ, TSLA, AAPL
NASDAQ · 07/02 20:24
Weekly Report: what happened at PTGX last week (0624-0628)?
Weekly Report · 07/01 11:12
BUZZ-U.S. STOCKS ON THE MOVE-Infinera, Landbridge, Tempus AI
The Nasdaq and the S&P 500 touched record highs on Friday. In-line inflation report strengthened hopes for interest rate cuts in September. Nike was set for its steepest one-day fall in over two decades after a gloomy forecast. Infinera, Landbridge and Tempus AI are up.
Reuters · 06/28 18:26
BUZZ-U.S. STOCKS ON THE MOVE-ARS Pharma, Digital Realty, Capricor Therapeutics
U.S. Stocks rose broadly on Friday. The Dow Jones Industrial Average was up 0.20% at 39,242.37. Nike shares slumped after a dismal annual sales forecast. The top three S&P 500 percentage gainers were Synchrony Financial, Steel Dynamics and Tilly's.
Reuters · 06/28 15:46
BUZZ-U.S. STOCKS ON THE MOVE-Protagonist Therapeutics, Infinera, GEO Group
Federal Reserve report shows inflation moderating in line with expectations. Dow e-minis poised for a higher open on Friday. Top three NYSE percentage gainers premarket: Nike, Infinera, GEO Group. Apple rises as China shipments in May rise about 40%.
Reuters · 06/28 13:13
Market-Moving News for June 28th
Trump Media & Technology Group shares trading higher following Thursday's presidential debate. Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma. Protagonist Therapeutic to join S&P SmallCap 600.
Benzinga · 06/28 12:37
BUZZ-Protagonist Therapeutics jumps on S&P SmallCap addition
Shares of Protagonist Therapeutics up 10.3% premarket to $35.16, a 2-week high. Co set to join S&P SmallCap 600 index this week. Biotech firm to replace Encore Wire WIRE.O in SPCY. Shares of PTGX up 39% YTD.
Reuters · 06/28 11:41
More
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist Ther through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).